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Abstract
This report discusses the aromatase enzyme and research of the inhibition of the
enzyme by natural products from plants. Aromatase is a cytochrome P450 enzyme
which catalyzes the conversion of androgens to estrogens. Due to the organization of
the aromatase C Y P l 9 gene, the enzyme undergoes tissue-specific expression,
including expression in adipose tissue and the ovary. Estrogen production by
aromatase is necessary for normal physiological development and activity in both
males and females. However, synthesis of estrogens by aromatase can contribute to
the development of estrogen-dependent diseases, such as breast and prostate cancer.
Current research in the field of plant natural products focuses on finding compounds
from plants which inhibit aromatase activity. Studies which utilized bioassays to test
plant compounds on aromatase activity have found that plant natural products are a
promising source of aromatase inhibitors. From cytotoxicity screenings, plant natural
products have also been concluded as potential new sources of anti-breast cancer
drugs. This research leads way to developing new drugs based upon natural products
for the treatment of estrogen-dependent disorders.
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Aromatase is the enzyme responsible for the conversion of androgens to estrogens.
Androgens and estrogens are steroid hormones found in both males and females. A n
example of the reactions which aromatase catalyzes includes the conversion of
androstenedione to estrone and testosterone to estradiol. Estrogens are present in the
ovaries, placenta, and testes, among other tissues. Estrogens have many functions,
including the production and distribution of body fat and the development of estrogendependent disorders, such as breast and prostate cancer (Monteiro and others 2006).
Estrogen interacts with the estrogen receptor in cells which leads to the proliferation
of cancer cells (Chen 1998).
Many types of cancers are estrogen-dependent, causing an increase in research
interest in the inhibition of aromatase activity. Inhibiting estrogen synthesis by
aromatase may lead to new forms of prevention and/or treatment of estrogendependent cancers. Natural products from plants is one area of interest in aromatase
research. Plants contain many compounds which display biological activity. This
suggests that some natural products may possess the ability to inhibit aromatase and,
therefore, prevent the development of estrogen-dependent cancers.
This report provides a detailed discussion of the aromatase enzyme, the role of the
estrogen receptor in estrogen-dependent cancers, and natural products research of
aromatase inhibition. The report begins by describing the mechanics and function of
aromatase, including a n analysis of aromatase from a genetic perspective. A
discussion of the estrogen receptor and its activity in different estrogen-dependent
cancers follows. The report concludes with a n analysis of research conducted on the
inhibition of aromatase by plant natural products, specifically the methods and results
of the research.

Aromatase is the product of the CYPl9 gene and catalyzes the formation of estrogens
from androgens via aromatization. The enzyme is found in many different organs and
tissues throughout the body, including the ovary, placenta, brain, and adipose tissue.
Aromatase activity is essential for normal function in these organs and tissues
(Simpson and others 2002).

The Aromatase Gene
The CYPl9 gene encodes aromatase cytochrome P450 (also known as P450arom and
aromatase). The location of the CYPl9 gene is 15q2 1.1, i.e. the long arm of
chromosome 15 on sub-band 1 of band 21 (NCBI 2008). The CYPl9 gene is part of the
P450 superfamily of genes. This superfamily has over 480 members in 74 families;
aromatase is the only member of family 19. The coding region of CYPl9 contains 9
exons which begin with exon 11. An exon is a region of a gene which codes for part of
the complete protein product of the gene and can contain untranslated regions
(NHGRI undated; Zhang 1998). Upstream of exon I1 a t the 5' end are a number of
exons (exon 1's) in the untranslated region of the gene (see Figure 1). Different tissues

contain a unique exon I in the 5' untranslated region (UTR) of the CYPl9 transcript
due to unique promoters. Transcription of C Y P l 9 a t different promoter sites is thus
tissue-specific. From Figure 1, the CYPl9 transcript in the placenta, adipose, brain,
and bone contain different 5'-UTR exon 1's due to their specific promoters. Though the
5'-UTR exons are different, the final transcript and translated aromatase enzyme are
the same for each tissue due to splicing which occurs to render the final CYPl9
transcript. As can be seen from Figure 1, this splicing occurs a t a n AGIGACT splice
acceptor site in exon 11. This allows the final transcript of the different tissues to
contain the same coding region, beginning a t exon 11. It is important to note that
aromatase expression in different tissues is under the control of different transcription
factors due to the tissue-specific promoters. Hence, the promoter for adipose tissue
may be under a different set of transcription factors than the promoter for bone, for
example (Simpson and others 2002).

Figure 1. Exon organization of the human CYP19 gene located on 15q21.1.
Values in kilobases (kb) indicate exon I distances from exon 11. Grey arrows indicate
the tissue-specific promoters. Also shown is the AG/GACT splice cite in exon 11.
Source: adapted from Simpson E; Clyne C; Rubin G; Chin Boon W; Robertson K; Britt K; Speed
C; Jones M. 2002. Aromatase - a brief overview. Annual Review of Physiology 64:93-127.

The Structure of Aromatase
The cytochromes, such as the cytochrome P450 superfarnily, are enzymes which
participate in electron or proton transfer reactions and contain one or more heme
groups (Anonymous 1997).Aromatase has many structural features which are
common to all cytochrome P450 proteins. These features include a heme-binding
region near the carboxyl end of the protein. This region contains a conserved cysteine
residue which acts as a fifth coordinating ligand for the heme iron. A thiolate ion (RSwhere R is a n alkyl group) in this region is responsible for many of the unique
spectrophotometric and catalytic properties of the cytochrome P450 proteins.
Upstream of this region are two regions highly conserved in aromatase species. The
first is a region of 20 amino acids, while the second region is believed to be part of the
substrate binding site which is near the heme prosthetic group where catalytic activity
occurs (Simpson and others 2002).
Due to the location of mammalian aromatase as a membrane-bound protein and its
low concentration in the endoplasmic reticulum of cells which express the protein,
obtaining a crystal structure of aromatase has been near impossible. However,
Graham-Lorence and others have modeled human aromatase based upon the threedimensional core structures of soluble bacterial cytochrome P450 proteins, with the
addition of secondary structures and other less-conserved features as was rational
(1995).
The authors have postulated the hydrophobic membrane-binding region of the protein,
which contains aliphatic and aromatic species which participate in recognition of the
substrate; a binding site for the redox partner; and residues involved in proper
orientation of the substrate for the active site (1995; Simpson and others 2002). Figure
2 illustrates this model.

Figure 2. Structure of the aromatase enzyme. The structural features are labeled;
the heme is the central red structure.
Source: Graharn-Lorence S; Arnarneh B; White R; Peterson J; Simpson E. 1995. A threedimensional model of aromatase cytochrome P450. Protein Science 4: 1065-80.

The core structure of aromatase, based upon the core structures of the bacterial P450
proteins, contains a bundle of four a-helices (helices D, E, I, and L), separate a-helices
J and K, and p sheets 1 and 2. Also in this core structure are the heme binding region
and a weaving "meander" region which extends from the N-terminal of the L helix
(Graham-Lorence and others 1995). Figure 3 shows the individual core features.

Figure 3. Core features of the aromatase enzyme. Note that the red structure is the
heme group.
Source: Graham-Lorence S; Amarneh B; White R; Peterson J; Simpson E. 1995. A threedimensional model of aromatase cytochrome P450. Protein Science 4: 1065-80.

The Aromatase Reaction
The cytochrome P450 proteins catalyze monooxygenation reactions. Aromatase
catalyzes the aromatization of C19 steroid hormones (the androgens) to estrogens in
the endoplasmic reticulum (Rainey and others 2003). This reaction is the sole reaction
in vertebrates to produce a phenyl ring. The reaction occurs in the presence of the
redox partner NADPH-P450 reductase and converts the A-ring of androgens to the
phenyl rings of estrogens, losing the methyl group a t carbon- 19 as a result (GrahamLorence and others 1995).
Via the reaction mechanism shown in Figure 4, aromatase converts androstenedione
to estrone and testosterone to estradiol (Monteiro and others 2006). The reaction uses
3 moles of oxygen and NADPH for every one mole of androgen substrate converted by
aromatase. The first two attacks by molecular oxygen in the reaction cause
hydroxylation of the methyl group at C-19 with the loss of water as a byproduct to
form a ketone. The third attack is a peroxidative attack on the methyl group which

results in the loss of the methyl group as formic acid and the production of the
aromatic phenyl ring of the estrogens. This last step completes the conversion of the
androgens to their estrogen counterparts (Graham-Lorence and others 1995).
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Figure 4. Conversion of androstenedione to estrone. 0 2 and NADPH are required
for the reaction to occur, while water and formic acid are released as byproducts.
Source: Graham-Lorence S; Arnarneh B; White R; Peterson J; Simpson E. 1995. A threedimensional model of aromatase cytochrome P450. Protein Science 4: 1065-80.
It is readily apparent how important structure of aromatase is to the enzyme's
catalytic function. For the reaction to take place, recognition of the androgen substrate
must occur and the substrate must be properly bound to the active site. The carbon a t
position 19 must be within 2 A of the oxygen bound to the heme region for attack by
the oxygen to occur. Also important is the binding of the redox partner NADPH and
the activation of oxygen by the heme region (Graham-Lorence and others 1995).

The Location of Aromatase
The aromatase enzyme is expressed in both males and females in a number of
different tissues and organs, including the ovary, adipose tissue, and bone. Expression
of aromatase is essential for production of estrogen in these organs and tissues. Lack
of the enzyme can have severe consequences in terms of regular physiological activity
dependent upon estrogen (Simpson and others 2002).

Aromatase Expression in the Ovary
Due to the tissue-specific promoters for the CYPl9 gene, expression of the gene in
different tissues is under the regulation of different transcription factors. Aromatase
expression occurs in the granulosa cells of the ovary, cells associated with the oocyte.
The gonadotropin follicle-secreting hormone (FSH) causes transcription of CYPl9 by
activating a signaling cascade (Bowen 2004). This signaling cascade eventually
activates transcription factors which bind to the CYPl9 promoter specific for the ovary
to begin transcription of aromatase (Simpson and others 2002).
In mice with a n aromatase knockout, the absence of estrogen production causes a n
impairment in sexual activity and development for both male and female mice. In male
mice, decreased sperm production and impaired sexual activity were the result of the
aromatase knockout. Similarly, the aromatase knockout in female mice resulted in
infertility due to the inability to ovulate (Simpson and others 2002).

Aromatase Expression in Adipose Tissue
The CYPl9 promoter specific for adipose tissue is under activation by the class I
cytokines, tumor necrosis factor-a (TNFa),and glucocorticoids (Simpson and others
2002). Cytohnes are small proteins which are secreted in response to certain stimuli;
they bind to membrane proteins and cause a response via secondary messengers for
the cell to change its behavior (Decker 2006). TNFa is a type of cytokine which has
both growth stimulatory and inhibitory effects (Anonymous 2000). Glucocorticoids are
compounds which have many different functions, including a role in glucose
metabolism and the breakdown of fat in adipose tissue. Certain glucocorticoids bind to
their receptors in the cell cytoplasm and translocate to the nucleus where they directly
regulate expression of their target gene (Bowen 2006).
In previous studies, aromatase deficiency in mice resulted in obesity, increased
number of fat droplets in the liver, and impairment of the fatty acid P-oxidation
pathway in liver cells. Obesity was also a result of aromatase deficiency in humans.
Also observed were increased cholesterol and high-density lipoprotein (HDL) blood
levels in aromatase knockout mice (Simpson and others 2002).

Aromatase Expression in Bone
Like expression in adipose tissue, expression of CYPl9 in osteoblast-like cells from
human bone samples is also under regulation by class I cytokines, TNFa, and
glucocorticoids. Also contributing to the regulation of aromatase expression is the
transforming growth factor-p 1 (TGF-P1)which has a role in cell proliferation and
differentiation (Hyytuainen and others 2004). Aromatase knockout in male and female
mice caused abnormal bone metabolism and growth, as well as decreased bone
density in the lumbar spine (Simpson and others 2002; WebMD 2006).

The Estrogen Receptor and
Estrogen-Dependent Cancers
Estrogens play a key role in the proliferation of estrogen-dependent disorders. Roughly
60% of premenopausal patients and 75% of postmenopausal patients suffer from
estrogen-dependent carcinomas. Estrogen regulates the development of estrogendependent disorders via its interaction with the estrogen receptor (ER) in cells.
Examples of estrogen-dependent cancers include breast, ovarian, and prostate cancer
(Chen 1998).

The Estrogen Receptor (ER)
Two mechanisms describe the function of the estrogen receptor and how estrogen
binds to the receptor. In the first mechanism, estrogen diffuses into the cell and binds
to the estrogen receptor which is in the nucleus. The estrogen-ER complex then binds
to estrogen response element (ERE) regulatory sequences in target genes. This binding
occurs directly or indirectly with the aid of activator protein 1 (AP1)or the
transcription factor SP1. Binding to the ERE sequences recruits coregulatory proteins
(whether coactivators or corepressors) which either activate or repress the promoter of
the target gene, leading to increased or decreased production of the mRNA and protein
corresponding to that gene. This cascade of events typically takes hours to occur
before producing a physiological response (Deroo and Korach 2006).
The second mechanism of the interaction of estrogen with the estrogen receptor
normally occurs within seconds or minutes. In this mechanism, estrogen either binds
to the estrogen receptor associated with the plasma membrane or binds to nonestrogen receptor proteins which are also associated with the plasma membrane.
Adaptor proteins play a role in locating the estrogen receptor to the cytoplasmic side of
the plasma membrane. This binding causes a n increase in the levels of Ca2+,NO, and
other small molecules, and causes kinase activation, all of which take part in signaling
(Deroo and Korach 2006). Figure 5 illustrates the two mechanisms of estrogen action
in the cell.
There are two forms of the estrogen receptor: ER a and ER p . These ER forms have
different expression patterns in tissues. The genes which encode ER a and ER p ESRl and ESR2, respectively - have different chromosomal locations (Deroo and
Korach 2006). The DNA-binding sites of ER a and ER p are 97% similar, differing in
only two amino acid residues. Likewise, the ligand-binding site of the two proteins is
59% similar in terms of amino acid sequence. Thus, ER a and ER p share DNA and
ligand binding characteristics (Par1 2000). Studies observing the results of mutations
in ER a and ER have found that mutations produce distinct phenotypes in the
animal models used, allowing for a better understanding of the physiological role of
these forms of the estrogen receptor (Deroo and Korach 2006).

Eslroaen or SERMs

Figure 5. The two mechanisms of interaction between estrogen and the estrogen
receptor (ER). Estrogen or selective estrogen receptor modulators (SERMs) enter
across the cell membrane and interact with the estrogen receptor in the nucleus or
bound to the plasma membrane. The mechanisms are described in the text. EBP,
estrogen-binding protein; CoReg, coregulatory protein; ERE, estrogen response
element.
Source: Deroo BJ; Korach KS. 2006. Estrogen receptors and human disease. The Journal of
Clinical Investigation 116(3):561-70.

The Estrogen Receptor and Breast Cancer
Previous studies have shown that increased exposure to estrogen causes a n increased
risk of developing breast cancer. There are two hypotheses which explain this
relationship between estrogen and breast cancer. The first hypothesis explains than
estrogen causes a n increase in the growth of mammary cells. Due to the increased
number of target cells, increased cell division will take place, allowing for a higher
chance of mutations to occur during replication. Detrimental effects to cell processes
such as apoptosis, cell growth, and DNA repair could result from mutations. Cancer
cells would thrive due to inhibition of apoptosis and DNA repair which naturally kill or
repair cancer cells, respectively. Mutations preventing regulation of cell growth would
allow uncontrolled proliferation of the cancerous cells. The second hypothesis
describes the metabolic byproducts of estrogen as causing DNA damage, resulting in
point mutations which can lead to cancer. Estrogen may participate in formation of
breast cancer by one or both mechanisms (Deroo and Korach 2006).

Previous studies conducted on animal models and cell cultures have revealed that the
estrogen receptor is a factor in the development of mammary glands and in mammary
cancer. Adult female mice with a n ERa knockout exhibited mammary glands which
were similar to those of prepubescent female mice, i.e. mammary glands that were not
fully developed. In other mouse studies, the ERa knockout either prevented, delayed,
or decreased tumor formation. Thus, ERa clearly has a role in regulating the activity of
estrogen in mammary gland maturation and cancer onset. Transcriptional
coregulators are also known to participate in estrogen-dependent tumor formation.
The coregulator amplified in breast cancer- 1 (AIB1) has increased expression in
certain breast tumors and affects tumor initiation and growth. The combined activity
of the estrogen receptor and transcriptional coregulators in the development of breast
tumors is still being understood (Deroo and Korach 2006).

The Estrogen Receptor and Ovarian Cancer
Ovarian cancer is the fifth most common cancer in women in the Unites States. The
majority of ovarian tumors form from the ovarian surface epithelium, while a smaller
number form from granulosa cells. While ERP is mostly expressed in tumors from
granulosa cells and expressed less in epithelium-derived tumors, ERa is expressed in
both epithelial and stromal tumors. The stroma is the framework which supports a n
organ and is normally comprised of connective tissue (MedicineNet.com 2003). In cell
culture studies, estrogens stimulated the growth of cancerous and normal ovarian
cells, while estrogen agonists inhibited growth of both cell types. As of yet, the exact
function of estrogens in cancerous and normal ovarian cell growth is not fully
comprehended (Deroo and Korach 2006).

The Estrogen Receptor and Prostate Cancer
Since the 1980s, the second leading cause of death in men due to cancer has been
prostate cancer. ERP is more prominent in human and rodent prostates than ERa.
While ERP is present in epithelial cells and, in lower quantities, in stromal cells, ERa is
only localized to stromal cells. Studies have shown that ERP expression levels decrease
in prostate tumors. Also observed in studies has been the formation of prostatic
epithelial hyperplasia, the excessive growth of normal cells, in ERP knockout mice
(MacDonald 2000). Similarly, rodents treated with agonists specific for ERP developed
prostate atrophy as a result of apoptosis. These findings suggest that ERP has a
necessary function in the healthy prostate (Deroo and Korach 2006).
Conversely, ERa is known to mediate the effect of estrogens in the prostate. Neonatal
rodents exposed to estrogens suffered from abnormal adult prostate function and
morphology, as well as inflammations, hyperplasia, and dysplasia (cells which are
abnormal but not cancerous) (Johns Hopkins Health Alerts 2007). Neonatal ERa
knockout rodents were not found to develop prostate hyperplasia upon exposure to
estrogens. Though studies have shed light on the contribution of the estrogen receptor
to prostate function, more research must be conducted to fully understand the role of
estrogens in prostate development (Deroo and Korach 2006).

Aromatase Inhibition by Plant Natural Products
The inhibition of aromatase for medicinal purposes has been studied quite extensively
in the field of natural products research, especially in regards to inhibition by natural
products from plants. Whether from animals, microbes, or plants, natural products
have historically been sources of therapeutic agents. This section begins with a brief
introduction to natural products drug discovery and discusses the methods, results,
and conclusions of studies conducted upon aromatase inhibition by plant natural
products.

Natural Products Drug Discovery
Natural products drug discovery is the study of chemical products from nature for new
medicinal treatments. Research of drugs from natural products by the Western
pharmaceutical industry
reached a climax between
1970 to 1980.
Approximately 49% of the
877 small molecules with
pharmaceutical
possibilities introduced
between 1981 and 2002
were natural products,
semi-synthetic natural
products, or synthetic
compounds based upon
natural products.
Approximately 25% of
drugs prescribed since the
1980s are natural
products or based upon
natural products (Koehn
and Carter 2005; Stokes
2007). As shown in Figure
6, drugs from natural
products treat a range of
illnesses.

Figure 6. Examples of natural products used for drug
purposes. Note the variety in the structures and their different
drug qualities.
Source: Koehn FE; Carter GT. 2005. The evolving role of natural
products in drug discovery. Nature Reviews Drug Discovery 4:206-20.

Natural Products from Plants
Due to their immense diversity, plants offer many drug possibilities. The initial step in
determining whether a natural product is active against a particular disease is to
isolate the natural product, i.e. isolate the pure compound. Many steps are involved in
the isolation process. First, a n extract or essential oil is obtained from a plant sample.
Extracts are collected by extraction of plant material, such as bark or root samples,
using a solvent. The solvent is typically somewhat polar like dichloromethane or
chloroform. Essential oils are obtained by hydrodistillation of finely chopped leaves,
followed by extraction with dichloromethane. In the next step, extracts are separated
into fractions using separation techniques which commonly include column
chromatography. Individual essential oils and fractions can then be tested in biological
screenings to determine which samples are active. Since the essential oils and
fractions are mixtures of compounds, this identifies which samples contain the active
compounds of interest. The active essential oils and fractions are then purified by
various techniques, including recrystallization and chromatography. Pure compounds
can then be structurally determined by nuclear magnetic resonance (NMR)or mass
spectrometry (MS).The pure compounds can be re-tested in the biological assays to
determine which compounds display biological activity (Koehn and Carter 2005;
Stokes 2007). Figure 7 outlines this process.

Test

fraction
Fractionate
(HPLC,

m,

Pure compound:
)Aw
Detm*le structure
(NMR, MS, W,
IR and so on)

Figure 7. Process of obtaining pure, active compounds from crude plant extracts.
The extract undergoes separation into fractions, followed by biological screening.
Active fractions are purified and screened again to isolate the active compounds in
their pure form.
Source: Koehn FE; Carter GT. 2005. The evolving role of natural products in drug discovery.
Nature Reviews Drug Discovery 4:206-20.

Monteiro and Others, 2006
In their study, Monteiro and others determined the effect of diet polyphenolic
compounds on the inhibition of aromatase. Polyphenolic beverages, such as wine and
tea, were also tested. Aromatase inhibition was measured using the tritiated water
release assay. The authors concluded that polyphenolic compounds do indeed inhibit
aromatase activity, but do not inhibit expression of the enzyme or cell viability (2006).

Background
The authors wished to study the effects of polyphenols on the inhibition of estrogen
synthesis by aromatase. Polyphenols are present in almost all plant-based foods. The
compounds contain the phenol structural unit, and many classes of polyphenols share
structural similarity with estrogens. This structural similarity opens the possibility
that polyphenols may be able to interfere with certain estrogen-dependent cellular
processes. Many polyphenol-rich beverages, such a s red wine and tea, have been
related to anticancer activity, including cell cycle regulation and impairment of cancer
cell activation (2006).

Methods
Monteiro and others measured aromatase inhibition by using the tritiated water
release assay. The assay works by measuring the release of tritiated water ([3H]H20)
during the conversion of tritiated androstenedione ([3H]androstenedione)to estrone.
Tritium, 3H, is a radioactive isotope of hydrogen. JAR cells were incubated with
samples of polyphenolic compounds and polyphenolic beverages, including red and
white wine, alcohol-free red and white wine, and black and green tea. The JAR cell line
originates from a placental tumor; the cell line was chosen for the experiment since
JAR cells are rich in aromatase (IST 2005). JAR cells were initially treated with
[3H]androstenedioneand then incubated with the various polyphenol samples. After
incubation, the cells were vortexed and centrifuged. The supernatant was collected
and the amount of [3H]Hz0 present in the supernatant was measured using liquid
scintillation counting. Liquid scintillation counting involves addition of the
supernatant to a scintillation cocktail which contains a n aromatic solvent. The beta
particles released from the decay of the radioactive isotope transfer their kinetic energy
to the solvent particles. When this energy excites the solvent particles, the solvent
particles emit UV light. This W light then excites fluor molecules in the solution
which emit blue light upon relaxation. A liquid scintillation counter measures the
pulses of blue light from the fluor molecules in the sample and converts the data to a
measure of the radioactivity of the sample (UWM undated; 2006).
To ensure that the polyphenols and beverages were not decreasing cell viability or
inhibiting expression of aromatase, the authors tested lactate dehydrogenase (LDH)
activity and conducted Western blotting and reverse-transcription polymerase chain
reaction (RT-PCR).Cell viability was determined by the release of LDH into the media,
which correlated linearly with cell death. LDH activity was measured by determining
the oxidation of NADH when pyruvate is reduced to lactate; LDH is the enzyme which
catalyzes the reduction reaction. RT-PCR and Western blotting demonstrated whether
aromatase was being expressed a t the mRNA and protein level, respectively (2006).

Results
Figure 8 shows the structure of the polyphenols tested in the study. Table 1 gives the
ICso values for a set of the polyphenols. The ICso value is the concentration of sample
required to inhibit aromatase activity by 50%. Thus, the lower the ICjovalue, the more
potent the sample. From Table 1, chrysin, naringenin, and quercetin were found to
have the most inhibitory effect against aromatase, while kaempferol, myricetin,
resveratrol had moderate inhibitory effect. Epigallocatechin-3-gallate had the least
inhibitory effect (Monteiro and others 2006).

Table 2 shows the aromatase inhibition of a second set of polyphenols; aromatase
activity is presented as a percent of the control. The solvent control (DMSO or ethanol,
depending on which solvent was used for that particular polyphenol) was taken as
100% aromatase activity. Catechin caused the most decreased aromatase activity,
followed by genistein and rutin. Epicatechin also had a significant decrease in activity,
but it was tested a t double the concentration of the other compounds in the table.
None of the polyphenols reduced cell viability or inhibited aromatase expression
(Monteiro and others 2006).

Figure 8. Structures of the polyphenols tested in the study. (a) catechin,
(b)chrysin, (c) daidzein, (d) epicatechin, (e) epigallocatechin-3-gallate, ( f ) genistein,
(g) kaempferol, (h) myricetin, (i) naringenin, U) quercetin, (k) resveratrol, and (1) rutin.
Source: Monteiro R; Azevedo I; Calhau C. 2006. Modulation of aromatase activity by diet
polyphenolic compounds. Journal of Agricultural Food Chemistry 54:3535-40.

Table 1. ICso values for a selection of the polyphenols.

phenolic compound

lCso(95% CI)
pmoK

dtrpin
naringenin
quercetin
kaempferol
myricetin
mratrol
epigallomhchin-3agaPate
Source: Monteiro R; Azevedo I; Calhau C. 2006. Modulation of aromatase activity by diet
polyphenolic compounds. Journal of Agricultural Food Chemistry 54:3535-40.

Table 2. Aromatase activity, reported as a percent of the control,
for a selection of the polyphenols.
phenolic
compound

amrnatase activity
(% of cantrot)

mnc
mmoln

catechin
epicatechin
genistein
mtin

6 4 . 2 5.5%b
~
60.5 k 21%b
740 t 6a0%b
779 + 3.7%b

2
1
1

1

Source: Monteiro R; Azevedo I; Calhau C. 2006. Modulation of aromatase activity by diet
polyphenolic compounds. Journal of Agricultural Food Chemistry 54:3535-40.
The beverages tested were red wine (RW),white wine (WW),alcohol-free red and white
wine (AF-RW and AF-WW, respectively), green tea (GT),and black tea (BT).Aromatase
activity was reported in units of pmol mg prot 1 h-I for RW, WW, and the controls (cells
with no treatment, C, and cells treated with ethanol, C'). These results are shown in
Figure 9(a).RW significantly decreased aromatase activity with respect to the cells that
were not treated. The ethanol control displayed the next highest decrease in activity,
followed by WW. Figure 9(b) shows aromatase activity, reported a s a percent of the
control, for AF-RW, AF-WW, GT, and BT. The controls were cells with no treatment, C,
and cells treated with sodium chloride, C'. The controls were set to 10O0/0 aromatase
activity. AF-RW caused the highest decrease in aromatase activity, followed by GT, BT,
and AF-WW. None of the beverages inhibited expression of aromatase or reduced cell
viability (Monteiro and others 2006).

Figure 9. Aromatase inhibitory activity of the polyphenolic beverages.
(a)Aromatase activity for red wine (RW) and white wine (WW).C, untreated cells; C',
cells treated with ethanol. (b)Aromatase activity for alcohol-free red and white wine
(AF-RW and AF-WW), green tea (GT), and black tea (BT). C, untreated cells; C', cells
treated with NaC1.
Source: Monteiro R; Azevedo I; Calhau C. 2006. Modulation of aromatase activity by diet
polyphenolic compounds. Journal of Agricultural Food Chemistry 54:3535-40.

Conclusions
While most of the polyphenols tested can be found in varying levels in both wine and
tea, chrysin is not found in any of the beverages tested. Likewise, naringenin is most
abundant in citrus fruits and is found in small quantities in red wine. The inhibitory
activity of the beverages can be attributed to their polyphenol content. RW and AF-RW
were found to be more active than WW and AF-WW, respectively. Generally, red wine
has approximately twenty times the content of polyphenols as WW. This occurs due to
the wine making process: grape skins are kept in contact with ethanol for a longer
period of time when making red wine versus white wine, allowing for more polyphenols
to be present in red wine. Due to the inhibitory activity of AF-RW and AF-WW, ethanol
was not concluded to be necessary for wine activity. Independent of wine, ethanol does
display its own inhibitory activity against aromatase (Monteiro and others 2006).
The mode of inhibition of these polyphenols is not clear. The authors hypothesize that
the compounds may interact with the aromatase enzyme, inhibiting aromatase activity
by blocking substrate binding. This is a possibility since the polyphenols are
structurally similar to the aromatase substrate. Also, the antioxidant properties of the
polyphenols may reduce NADPH and 0 2 availability, both of which are necessary for
the aromatase reaction to proceed. No matter the mechanism of the polyphenols, their
inhibitory activity against aromatase makes the compounds possible drug candidates
for treatment of estrogen-dependent disorders (2006).

Ta and Walle, 2007
In their study, Ta and Walle tested the aromatase inhibitory activity of the methylated
flavones 5,7-dimethoxyflavone, 7-methoxyflavone, and 7,4'-dimethoxyflavone versus
their non-methylated counterparts chrysin, 7-hydroxyflavone, and 7,4'dihydroxyflavone, respectively. The authors used a high-throughput aromatase assay
for their study (2007).

Background
Flavonoids are naturally occurring compounds in plants. It is known that methylated
flavones, a class of flavonoids, have better intestinal absorption and resistance to
metabolism than their non-methylated counterparts. As such, methylated flavones
would be better pharmaceuticals. In this study, the authors tested the inhibitory effect
of methylated flavones against aromatase in comparison to the non-methylated
equivalents which are known to inhibit aromatase. The methylated flavones could
prove to be new drug candidates if they are effective against aromatase (2007).

Method
The compounds tested in the study were chrysin, 7-hydroxyflavone (7-HF),and 7,4'dihydroxyflavone (7,4'-DHF) and their methylated counterparts 5,7-dimethoxyflavone
(5,7-DMF),7-methoxyflavone (7-MF),and 7,4'-dimethoxyflavone (7,4'-DMF). The
structures of the compounds are shown in Figure 10. The aromatase assay conducted
was a n enzymatic assay. The aromatase enzyme was obtained from recombinant
human CYP19. The compounds were diluted by serial dilution to concentrations of
0.05-100 pM and then added to a n NADPH-generating system in phosphate buffer.
After a brief incubation period, aromatase and dibenzylfluorescein (DBF) substrate

were added. The procedure was conducted in 96-well plates. The reaction was
terminated by the addition of sodium hydroxide and, two hours later, fluorescence was
measured using a plate reader. A triplicate test was performed for each concentration
of the flavones. The assay gave a measure of aromatase activity since DBF fluoresces
upon metabolism by aromatase. Thus, the more fluorescence, the more aromatase
activity (Ta and Walle 2007).

7 hll

Figure 10. Structures of the flavones tested in the study. Substituents at the 4', 5,
and 7 positions vary for each compound.
Source: Ta N; Walle T. 2007. Aromatase inhibition by bioavailable methylated flavones. Journal
of Steroid Biochemistry and Molecular Biology 107:127-9.

Results
Figure 11 shows the results of the study. Graphs are depicted as aromatase activity a s
a percent of the control (the control taken as 100%) versus concentration of the
compound in yM units. The authors found that 5,7-DMF had very poor inhibition
against aromatase in comparison to its counterpart, chrysin, which is a very potent
aromatase inhibitor. Conversely, 7-MF and 7,4'-DMF had very similar inhibition in
comparison to their respective counterparts, 7-DF and 7,4'-DHF, which are the two
most potent aromatase inhibitors of the flavones (Ta and Walle 2007).

001
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10
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Figure 11. Aromatase activity as a function of concentration of the flavone
samples. Aromatase activity for (a) 5,7-dimethoxyflavone and chrysin, (b) 7methoxyflavone and 7-hydroxyflavone, and (c) 7,4'-dimethoxyflavone and 7,4'dihydroxyflavone. The methylated flavones are represented by the white squares, while
the black dots represent the unmethylated counterparts.
Source: Ta N; Walle T. 2007. Aromatase inhibition by bioavailable methylated flavones. Journal
of Steroid Biochemistry and Molecular Biology 107: 127-9.

Conclusions
The methylated flavones, such as 7-MF and 7,4'-DMF, have better resistance against
metabolism in the human liver and have better intestinal absorption versus their nonmethylated equivalents. Due to the high aromatase inhibition of 7-MF and 7,4'-DMF,
the compounds are excellent candidates as anti-aromatase drugs in humans. Though
the compounds used in the study were synthetic, both compounds are found naturally
in plants. 7-MF is found in Meliaceae and Rutaceae plants, while 7,4'-DMF has been
found in neotropical nutmeg species and propolis, the resin created by bees from plant
products (Ta and Walle 2007; NLM 2008).

Inhibition of Aromatase by Plant Extracts and
Essential Oils from Costa Rica
A study was performed test the inhibitory effect of plant extracts and essential oils
obtained from Monteverde, Costa Rica, against aromatase activity. The study was
conducted by the author of this report through the Natural Products Drug Discovery
Group at the University of Alabama in Huntsville, under the direction of Dr. William N.
Setzer. The natural products were previously tested by the author for cytotoxic activity
against breast cancer cells. An enzymatic fluorescence assay was the method of choice
for testing aromatase inhibition by the plant samples. While the study concluded the
natural products to have excellent cytotoxic abilities, results of the aromatase
inhibition assay are, as of yet, inconclusive.

Background
The natural product samples tested in this study were obtained from the rainforests of
Monteverde, Costa Rica. Natural products from Costa Rica are of particular interest
due to the many drug possibilities which exist in the rainforests. Between 1983 and
1995, more than 60% of new drugs approved for the treatment of cancer and
infections were based on natural products from tropical rainforest plants. Multiple
surveys of the bioactivity of plants collected in Monteverde, Costa Rica, have yielded
cytotoxic, antibacterial, antifungal, and antiviral activity. The wealth of biodiversity in
the Monteverde region lends credence that the rainforests yet contain many potential
medicinal agents. (Setzer and others 2003)

Plant materials - including bark, roots, and leaves - were collected in the rainforests of
the Monteverde region in May 2008. All materials were finely chopped. From bark and
roots, crude extracts were obtained by Soxhlet extraction with solvents including
acetone, chloroform, dichloromethane, and methanol. Essential oils were collected by
the hydrodistillation of leaves with chloroform using a Likens-Nickerson apparatus.
The extracts and essential oils were prepared as 1% w/w dimethylsulfoxide (DMSO)
solutions for subsequent testing in cytotoxicity and aromatase inhibition assays.

MTT Assay
The DMSO samples of the crude extracts and essential oils were initially tested for
cytotoxicity against the MDA-MB-23 1 breast cancer cell line. Cytotoxicity was
determined by testing for cell viability using the MTT cell proliferation assay. A total of
sixty-six DMSO samples were tested in the assay. The assay works by measuring
product formation from a chemical reaction carried out by living cells. Live cells
treated with the yellow compound MTT (3-(4,5-Dimethylthiazol-2-y1)-2,5Diphenyltetrazolium bromide) reduce MTT to the purple compound formazan, a
reaction catalyzed by the enzyme mitochondrial reductase. This reaction is shown in
Figure 12. Thus, this test offers a n easy method by which to detect live cells since
dead cells cannot produce formazan. (Biocompare 2009)

mitochondrial
reductase

MTT

Formazan

Figure 12. Conversion of MTT to formazan by mitochondrial reductase. M l T is a
bright yellow compound, while formazan is deep purple in color.
Source: Biocompare. 2009. Influence of washing steps on cell attachment: Comparison of PDL
coated and cell culture treated microplates.
http:/ /www.biocompare.com/Articles/TechnicalArticle/1605/Influence-Of-Washing-Steps-OnCell-Attachment-Comparison-Of-PDL-coated-And-Cell-Culture-Treated-Microplates-fromGreiner-Bio-One.htm1. Accessed 2009 April 2 1.
The author used the following method for performing the M l T assay. Breast cancer
cells grown in a 96-well plate were treated with a selection of DMSO samples. The
samples were tested in quadruplicate a t a concentration of 100 ,ug/mL. The negative
controls in the assay were growth media and DMSO, while the positive control was the
compound tingenone. Tingenone was the positive control due to its highly cytotoxic
nature, being cytotoxic even a t relatively low concentrations (Setzer and others 1998).
The cells were then incubated with the samples for 48 hours. After incubation, MTT
was added to each well and the plate was allowed to incubate for a further 4 hours.
Before incubation, however, the plate was pre-read in a spectrophotometer to obtain
initial absorbance readings at a wavelength of 570 nm. After the 4-hour incubation
period, the production of purple formazan was observed if live cells were present. The
plate was read once more in the spectrophotometer to obtain final absorbance
readings at the same wavelength. Initial and final absorbance readings were tabulated
in a spreadsheet and entered into equations to determine the percentage of viable cells
remaining after treatment with each sample. From the percent viable cells, the percent
kill of the sample was calculated.

Aromatase Inhibition Assay
The aromatase inhibition assay conducted in the study was performed using a
CYP19/MFC high throughput inhibitor screening kit purchased from BD Gentest
Corporation (Cat #459520). The assay is a n enzymatic fluorescence assay, measuring
the production of a fluorescent compound by active aromatase. Aromatase converts
the compound methoxy-4-trifluoromethyl-coumarin (MFC) to the fluorescent
compound 7-hydroxy-4-trifluoromethyl coumarin (7-HFC).This reaction is shown in
Figure 13. (BD Biosciences 2009)

aromatase

.

MFC

Figure 13. Conversion of MFC to 7-HFC by aromatase. 7-HFC is a highly
fluorescent compound.
Source: Sigma-Aldrich. 2009. 7-Methoxy-4-(trifluoromethy1)coumarin.
http: / /www.sigmaaldrich.com/catalog/ProductDetail.do?N4=T3
165 I SIGMA&N5=SEARCH_CO
NCAT-PNO I BRAND-KEY&F=SPEC. Accessed 2009 Apr 2 1.
Sigma-Aldrich. 2009. 7-Hydroxy-4-(trifluoromethy1)coumarin.
http: / /www.sigmaaldrich.com/catalog/ProductDetail.do?N4=368512 I ALDRICH&N5=SEARCH7
CONCAT-PNO I BRAND-KEY&F=SPEC. Accessed 2009 Apr 2 1.

The assay works by treating the aromatase enzyme with the various samples to be
tested in a solid black 96-well plate. This particular type of plate is necessary for
measuring fluorescence readings. For the amounts of reagents present in the kit,
thirty samples can be tested in duplicate at the initial concentration of choice; serial
dilution of the samples is performed in the plate. The negative control includes all of
the reagents minus a n inhibitor, while the positive control is the known aromatase
inhibitor ketoconazole (KTZ).MFC is then added to the mix and the reaction between
MFC and aromatase is allowed to occur. After addition of a stop reagent to halt the
reaction, the plate is placed in a spectrophotometer to measure fluorescence readings.
The excitation and emission wavelengths are 409 nm and 530 nm, respectively.
Fluorescence indicates the presence of 7-HFC and, therefore, active aromatase not
inhibited by the samples. From the fluorescence readings, the concentration of sample
to cause 50% inhibition of aromatase activity (ICstl) can be calculated. (BD Biosciences
2009)

Results
Table 3 shows the results for the cytotoxicity screenings using the MTT assay. From a
total of sixty-six samples of crude extracts and essential oils, eleven samples were
found to show activity against the MDA-MB-231 breast cancer cells. An "active"
sample was defined as any which displayed a percent kill of 90% or higher. Certain
samples were tested in multiple trials, hence multiple percent kill values are available
for those samples.

Table 3. MTT assay results for the active crude extract and essential oil samples.
Results are given as % kill values with standard deviations (0).
A total of sixty-six
samples were tested in the assay.
Crude Extract
Tapirira mexicana bark
(chloroform)

% Kill

a (%)

83.11
87.71
90.98
97.35

7.2 1
0.97
2.09
0.86

Salacia sp. "liana" bark
(dichloromethane)
Verbesina turbacensis bark
(acetone)
Bursera ovalifolia bark
(chloroform)
Verbesina turbacensis root
(acetone)

Essential Oil
Rhodostemonodaphne kunthiana

% Kill

a (%)

90.61

14.58

Guatteria dispy roides

98.83

1.67

Desmopsis bibracteata

99.3 1

1.10

Schefflera rod rigueziana

99.60

0.68

101.54

0.89

Montanoa guatemalensis
(leaf essential oil #2)
Cymbopetalum costaricense

For the aromatase inhibition assay, results have not yet been confirmed by the
author's efforts. Errors have been detected in the fluorescence readings for the
controls in trial runs. Fluorescence readings for the positive and negative controls
have been very similar, when readings for the positive control should be significantly
lower than readings for the negative control due to decreased production of 7-HFC.
Possibilities for these observed results include solvent and enzyme issues. The solvent
used in the assay to dissolve the samples, DMSO, may be exhibiting inhibitory effects
against the aromatase enzyme. Also, the aromatase enzyme itself used in the assay
may be faulty and, thus, not catalyzing the conversion of MFC to 7-HFC as expected.

Conclusions
From the results of the MTT assays, the crude extracts and essential oils obtained
from Costa Rica can be concluded as promising sources of new anti-breast cancer
drugs. However, to determine the inhibitory effect of the samples against aromatase,

further testing using the aromatase inhibition assay must be conducted. Results of
the aromatase assay will be conclusive once errors with fluorescence readings are
resolved.
In terms of what is responsible for the cytotoxicity of the active samples, the
compounds present in the samples must be known. The activity displayed by the
Salacia "liana" species may be due to the presence of tingenone in the extract, while
bornyl caffeate may contribute to the activity of the Verbesina turbacensis extracts.
Tingenone, which has previously been isolated from the bark extract of the Salacia
"liana" species, is highly cytotoxic. ICso values for tingenone against different cancer
cell lines are 1.9 pM (H4IIE))2.7 pM (Hep-G2),and 1.7 pM (SK-Mel-28) (Setzer and
others 1998). Similarly, bornyl caffeate, which has been isolated from Verbesina
turbacensis, has been shown to display antitumor activity in other studies utilizing the
MTT assay (Arnaro-Luis and others 2002; Xia and others 2008).
Further research must be conducted to determine which specific compounds in the
extracts and essential oils are responsible for observed activity. This will involve
isolation and purification of compounds from the active samples. Isolation and
purification techniques include column chromatography and gas chromatographymass spectrometry (GC-MS),for example. Structural determination for purified
compounds would then be conducted using nuclear magnetic resonance (NMR).
Purified compounds would undergo subsequent screening in MTT assays to conclude
individual cytotoxic activities. Synergism studies would also be beneficial to determine
if any compounds present in the samples work in synergy to cause cytotoxicity.

The role of aromatase in estrogen synthesis makes the enzyme a prime target for
drugs treating estrogen-dependent diseases. The interaction of estrogen with the
estrogen receptor in certain tissue cells can increase the development of cancer such
as breast, ovarian, and prostate cancer. Thus, regulating estrogen production by
aromatase to allow for normal cell development but decreased development of tumor
cells is key in preventing and treating these estrogen-dependent cancers.
Increasingly, researchers are looking towards natural products from plants as sources
of new medicines. Plants offer a n immense diversity of natural products, increasing
the likelihood of discovering bioactive compounds from the vast amount of natural
products available. For example, from cytotoxicity screenings conducted by the
author, natural products from Costa Rica were found to be promising sources of new
anti-breast cancer drugs. In terms of targeting aromatase, such natural products from
plants would need to inhibit aromatase catalytic activity. In other words, inhibit
aromatase production of estrogens. From previous studies of aromatase inhibition by
natural products from plants - such as the study by Monteiro and others and the
research conducted by Ta and Walle - various compounds from plants were found to
show aromatase inhibitory activity. This affirms that plant are a promising source of
aromatase inhibitors.
Further research is still in order before creating a n anti-aromatase drug from a
natural product. More bioactivity tests are required, as well as research of the in vivo
activity of bioactive plant compounds. Indeed, the activity and efficacy of a drug once

it is in the human body is of immense importance in determining drug safety and
dosage amounts. Though so much research is still to be done, the discovery of new
drugs as treatment, and hopefully a cure, for devastating illnesses like cancer is well
worth the journey.
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